Cis-targeted Immunotherapies Need Large CDMO Expertise but also Flexibility

Asher Biotherapeutics is developing a pipeline of cis-targeted immunotherapies that selectively activate only the immune cell types that drive the desired therapeutic response. The company was seeking a contract development and manufacturing organization (CDMO) that could handle Phase 2 through to commercial production of its lead candidates, as well taking early-stage projects in its pipeline all the way through their lifecycle. The technical capability and capacity of a large CDMO like Lonza was attractive, but Asher wanted to be sure that a large provider would be committed to its pipeline and offer flexibility in terms of technical approach and program structuring.